Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STARS
2024-516215-24-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Takayasu arteritis (TAK) comparing Secukinumab arm with Standard of care arm (2 arms). Primary endpoints: Disease remission with prednisone discontinuation at 6 months, NIH criterion 1 systemic features and 3 more. Planned start Feb 2026; status: authorised.
02
Drugs
secukinumab
03
Conditions
Takayasu arteritis (TAK)
Beyond the preview
Go deeper on 2024-516215-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516215-24-00.